- Home
- SLG vs DYN Comparison
SLG vs DYN Comparison
Compare SLG & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLG | DYN |
|---|---|---|
| Founded | 1980 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.8B |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SLG | DYN |
|---|---|---|
| Price | $47.05 | $14.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 17 |
| Target Price | ★ $57.62 | $35.73 |
| AVG Volume (30 Days) | 833.1K | ★ 3.0M |
| Earning Date | 10-21-2026 | 11-04-2026 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,003,046,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.18 | N/A |
| 52 Week Low | $34.77 | $14.00 |
| 52 Week High | $60.09 | $27.31 |
Technical Indicators
Market Signals| Indicator | SLG | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 33.87 | 27.68 |
| Support Level | $44.08 | N/A |
| Resistance Level | $46.90 | $19.46 |
| Average True Range (ATR) | 1.59 | 0.74 |
| MACD | -0.07 | 0.16 |
| Stochastic Oscillator | 24.42 | 4.29 |
Price Performance
Historical ComparisonAbout SLG SL Green Realty Corp
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 30.6 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.